| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.ATV.12.2.135 |
| P953 | full work available at URL | https://www.ahajournals.org/doi/pdf/10.1161/01.ATV.12.2.135 |
| P698 | PubMed publication ID | 1311945 |
| P2093 | author name string | C. T. Esmon | |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | anticoagulation | Q63279445 |
| Cardiology and cardiovascular medicine | Q96320350 | ||
| anticoagulant | Q215118 | ||
| P304 | page(s) | 135-145 | |
| P577 | publication date | 1992-02-01 | |
| P1433 | published in | Arteriosclerosis and thrombosis : a journal of vascular biology | Q27709770 |
| P1476 | title | The protein C anticoagulant pathway | |
| P478 | volume | 12 |
| Q36495558 | A Syrian golden hamster model recapitulating ebola hemorrhagic fever |
| Q40868635 | Abnormalities of hemostasis in ischemic stroke. |
| Q35974913 | Activated Protein C Does Not Alleviate the Course of Systemic Inflammation in the APCAP Trial. |
| Q39798451 | Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein c reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation |
| Q42904795 | Activated protein C increases sensitivity to vasoconstriction in rabbit Escherichia coli endotoxin-induced shock. |
| Q74026795 | Activated protein C reduces the ischemia/reperfusion-induced spinal cord injury in rats by inhibiting neutrophil activation |
| Q56765885 | Activated protein C reduces the severity of compression-induced spinal cord injury in rats by inhibiting activation of leukocytes |
| Q41137636 | Activated protein C resistance: from phenotype to genotype and clinical practice. |
| Q74292657 | Alpha 2-macroglobulin enhances prothrombin activation and thrombin potential by inhibiting the anticoagulant protein C/protein S system in cord and adult plasma |
| Q51833118 | Analysis of endothelial protein C receptor gene and metabolic profile in Prader-Willi syndrome and obese subjects. |
| Q78513912 | Analysis of the thrombomodulin gene in patients with venous thrombosis |
| Q37368145 | Anticoagulant synergism of heparin and activated protein C in vitro. Role of a novel anticoagulant mechanism of heparin, enhancement of inactivation of factor V by activated protein C |
| Q35177118 | Antiphospholipid Antibodies: Proposed Mechanisms of Action |
| Q37419860 | Antithrombotic Effects of Nur77 and Nor1 Are Mediated Through Upregulating Thrombomodulin Expression in Endothelial Cells |
| Q41157164 | Antithrombotic and fibrinolytic factors. A review |
| Q42828832 | Binding of recombinant annexin V to endothelial cells: effect of annexin V binding on endothelial-cell-mediated thrombin formation |
| Q39149359 | Biological Insights into Therapeutic Protein Modifications throughout Trafficking and Their Biopharmaceutical Applications |
| Q54080510 | Cardiopulmonary bypass and activation of antithrombotic plasma protein C. |
| Q73555664 | Clinical and laboratory effects of recombinant human activated protein C in the treatment of a patient with sepsis-induced multiple organ failure |
| Q24801879 | Clinical review: Drotrecogin alfa (activated) as adjunctive therapy for severe sepsis--practical aspects at the bedside and patient identification |
| Q36280688 | Cluster analysis of consensus water sites in thrombin and trypsin shows conservation between serine proteases and contributions to ligand specificity |
| Q95314016 | Commentary |
| Q35042922 | Conclusions: drotrecogin alfa (activated)--from bench to practical use at the bedside |
| Q36176667 | Design and characterization of an APC-specific serpin for the treatment of hemophilia. |
| Q45889584 | Development and disease in proteinase-deficient mice: role of the plasminogen, matrix metalloproteinase and coagulation system |
| Q77631620 | Dynamics of clot growth induced by thrombin diffusing into nonstirred citrate human plasma |
| Q99401507 | Endothelial JAK2V617F mutation leads to thrombosis, vasculopathy, and cardiomyopathy in a murine model of myeloproliferative neoplasm |
| Q34956516 | Engineering the proteolytic specificity of activated protein C improves its pharmacological properties |
| Q40304955 | Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells |
| Q35300007 | Host response dynamics following lethal infection of rhesus macaques with Zaire ebolavirus |
| Q47224100 | In vitro and in vivo properties of bicyclic lactam inhibitors: a novel class of low molecular weight peptidomimetic thrombin inhibitors |
| Q73591502 | In vitro studies on the effect of activated protein C on platelet activation and thrombin generation |
| Q35281560 | Inhibition of transforming growth factor-β restores endothelial thromboresistance in vein grafts |
| Q42714463 | Is There NO Treatment For Severe Sepsis? |
| Q41024567 | Laboratory diagnosis of hemorrhagic and thrombotic disorders. |
| Q40458722 | Molecular Genetics of Venous Thromboembolism |
| Q34340007 | Mutation in blood coagulation factor V associated with resistance to activated protein C. |
| Q41746195 | Neonatal brain injury and systemic inflammation: modulation by activated protein C ex vivo. |
| Q36259602 | New insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated). |
| Q90706575 | Pediatric Intensive Care: Immunomodulation With Activated Protein C ex vivo |
| Q54151687 | Phenprocoumon-induced hepatitis delaying precise diagnosis in a thrombophilic patient with activated protein C resistance due to factor V R506Q mutation. |
| Q34181688 | Physiological anticoagulation. Resistance to activated protein C and venous thromboembolism |
| Q37364238 | Proteasome inhibitors enhance endothelial thrombomodulin expression via induction of Krüppel-like transcription factors |
| Q37784567 | Protein C as an early biomarker to distinguish pneumonia from sepsis |
| Q28509678 | Prothrombotic phenotype of protein Z deficiency |
| Q73127978 | Reduced C4b-binding protein in preeclampsia |
| Q34334154 | Report of the NASPE/NHLBI Round Table on Future Research Directions in Atrial Fibrillation. North American Society of Pacing and Electrophysiology |
| Q93137193 | Revisiting the activated protein C-protein S-thrombomodulin ternary pathway: Impact of new understanding on its laboratory investigation |
| Q24794551 | Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis |
| Q72781709 | Scanning method to establish the molecular basis of protein C deficiencies |
| Q78772829 | Severe sepsis |
| Q77403293 | Spinal cord injury in the rat |
| Q36467579 | The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis |
| Q77291965 | The presence of infection-related antiphospholipid antibodies in infective endocarditis determines a major risk factor for embolic events |
| Q36229803 | The prothrombotic phenotypes in familial protein C deficiency are differentiated by computational modeling of thrombin generation |
| Q33728350 | The role of tissue factor and factor VIIa in hemostasis |
| Q59054069 | The thrombin paradox |
| Q38290368 | Two Mutations in the Promoter Region of the Human Protein C Gene Both Cause Type I Protein C Deficiency by Disruption of Two HNF-3 Binding Sites |
| Q41897839 | Unique distance- and DNA-turn-dependent interactions in the human protein C gene promoter confer submaximal transcriptional activity |
| Q50945162 | Use of drotrecogin alpha (recombinant human activated protein C, rhAPC) in the treatment of severe sepsis induced by graft pancreatitis after simultaneous pancreas and kidney transplantation: a case report. |
Search more.